Hypoxia and Medicine

Shingles Medical Condition News

'Severely ill' widow died two days after care home moveFriday, September 3, 2010 @ 12:12AMAN ELDERLY widow was so "acutely and severely ill" when she was taken to hospital from a privately-run care home that she died two days later, an inquest heard.

One man race Former Borgess coach McGreevy battles his way back to coaching professionThursday, September 2, 2010 @ 8:03AMJohn McGreevy has coached many runners and watched many races in his lifetime.

Inhibitex Successfully Completes Phase 1a Trial of INX-189Wednesday, September 1, 2010 @ 6:16AMATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg ...

Inhibitex Successfully Completes Phase 1a Trial of INX-189Wednesday, September 1, 2010 @ 6:00AMATLANTA----Inhibitex, Inc. , announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections.

The Fourth Product Candidate Containing Antigenics' QS-21 In Phase 3 Clinical DevelopmentFriday, August 27, 2010 @ 7:36AMAntigenics, Inc. (NASDAQ:AGEN) announced that GlaxoSmithKline's (GSK) herpes zoster vaccine candidate, which contains Antigenics' QS-21 Stimulon® adjuvant as a key component, has commenced Phase 3 clinical trials for the prevention of shingles. GSK plans to study more than 30,000 patients globally for the debilitating condition which currently has limited treatment and prevention options ...